Arch Therapeutics Announces Participation at the 2013 Boulder Peptide Symposium in Colorado September 25-27

Arch Therapeutics Announces Participation at the 2013 Boulder Peptide Symposium 
in Colorado September 25-27 
CAMBRIDGE, MA -- (Marketwired) -- 09/20/13 --   Arch Therapeutics,
Inc. (OTCQB: ARTH) ("Arch" or the "Company"), today announced it will
be featured as a presenting company at the Boulder Peptide Symposium
2013. The conference is being held September 25-27, 2013, at the St
Julien Hotel in Boulder, Colorado. 
Terrence W. Norchi, MD, CEO of Arch Therapeutics, will provide an
overview of the medical device Company's plan to commercialize novel
products using their proprietary self-assembling peptide technology
during a live presentation to a significant audience of conference
attendees. If you are a member of the industry or a non-profit,
academic, or government group, and would like to attend the Company's
presentation, please click on the following link to register for the Boulder Peptide Symposium
About Arch Therapeutics, Inc. (OTCQB: ARTH)
 Arch Therapeutics, Inc.
is a medical device company developing a novel approach to stop
bleeding (hemostasis) and control leaking (sealant) during surgery
and trauma care. Arch is developing products based on an innovative
self-assembling peptide technology platform to make surgery and
interventional care faster and safer for patients. Arch's flagship
development stage product candidate, known as AC5(TM), is being
designed to achieve hemostasis in minimally invasive and open
surgical procedures. Find out more at  
About Boulder Peptide Society
 The Boulder Peptide Society is a
non-profit 501(3)c organization dedicated to supporting the
advancement of peptide therapeutics. The Society organizes the Annual
Boulder Peptide Symposium as a key vehicle for driving the science
and technology in this important field. 
Notice Regarding Forward-Looking Statements
 This news release
contains "forward-looking statements" as that term is defined in
Section 27(a) of the Securities Act of 1933, as amended, and Section
21(e) of the Securities Exchange Act of 1934, as amended. Statements
in this press release that are not purely historical are
forward-looking statements and include any statements regarding
beliefs, plans, expectations or intentions regarding
 the future. Such
forward-looking statements include, among other things, references to
novel technologies and methods, our business and product development
plans and projections, or market information. Actual results could
differ from those projected in any forward-looking statements due to
numerous factors. Such factors include, among others, the inherent
uncertainties associated with developing new products or technologies
and operating as a development stage company, our ability to retain
important members of our management team and attract other qualified
personnel, our ability to raise the additional funding we will need
to continue to pursue our business and product development plans, our
ability to develop and commercialize products based on our technology
platform, and market conditions. These forward-looking statements are
made as of the date of this news release, and we assume no obligation
to update the forward-looking statements, or to update the reasons
why actual results could differ from those projected in the
forward-looking statements. Although we believe that any beliefs,
plans, expectations and intentions contained in this press release
are reasonable, there can be no assurance that any such beliefs,
plans, expectations or intentions will prove to be accurate.
Investors should consult all of the information set forth herein and
should also refer to the risk factors disclosure outlined in the
reports and other documents we file with the SEC, available at 
On Behalf of the Board,
 Terrence W. Norchi, MD.
 Arch Therapeutics,
ARTH Investor Relations
Toll Free: +1-855-340-ARTH (2784) (US and Canada)
Press spacebar to pause and continue. Press esc to stop.